For the Inventor, By the Inventor

Enter assignee name

Boulogne-Billancourt, France

Pierre Fabre Medicament

USPTO Granted Patents = 266

CIPO Patents = 27

EPO Patents = 134

Trademarks = 7

Forward Citations = 1,168

Loading Chart...

Loading Chart...

317 inventors (with patents filed for the assignee):

Liliane Goetsch (42 out of 44 patents)

Michel Perez (24 out of 24 patents)

Bernard Vacher (22 out of 22 patents)

4. Thierry Imbert (20 out of 22 patents)

5. Jean-François Haeuw (18 out of 18 patents)

6. Nathalie Corvaia (14 out of 15 patents)

7. Yves Guminski (13 out of 14 patents)

8. Wouter Koek (13 out of 13 patents)

9. Marie Lamothe (12 out of 12 patents)

10. Alexandra Jouhanneaud (12 out of 12 patents)

11. Elisabeth Dupont-Passelaigue (11 out of 11 patents)

12. Dennis C Bigg (11 out of 23 patents)

13. Charlotte Beau-Larvor (10 out of 11 patents)

14. Anna Kruczynski (10 out of 10 patents)

15. Joël Bougaret (10 out of 12 patents)

Core Competencies:

Antibody-Drug-Conjugate

Cancer Treatment

Movement Disorders

RAFKinase Inhibitors

Immunocytokines

Transdermal Devices

C10orf54 Antibodies

IGF-1R Antibodies

Dopamine D3 Receptor Antagonists

Quinazoline Derivatives

Celastrol Derivatives

Macrolides

266 patents: Sort by Forward Citations

1. 12472169 - Method for treating movement disorders with befiradol (2025-11-18),

2. 12312336 - Inhibitors of RAF kinases (2025-05-27),

3. 12209129 - Anti-Met fab-Fc for the treatment of a tumor and/or metastasis (2025-01-28),

4. 12011485 - Sulfomaleimide-based linkers and corresponding conjugates (2024-06-18),

5. 11918656 - Antibody-drug-conjugate and its use for the treatment of cancer (2024-03-05),

6. 11873339 - Anti-C10orf54 antibodies and uses thereof (2024-01-16),

7. 11673931 - Immunocytokines for the treatment of cancer (2023-06-13),

8. 11661457 - IGF-1R antibody-drug-conjugate and its use for the treatment of cancer (2023-05-30),

9. 11517625 - Antibody-drug-conjugate and its use for the treatment of cancer (2022-12-06),

10. 11365259 - IGF-1R antibody and its use as addressing vehicle for the treatment of cancer (2022-06-21),

11. 11340233 - Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples (2022-05-24),

12. 11311591 - Use of copaifera oleoresin in pathologies of the prostate (2022-04-26),

13. 11219693 - Antibody-drug-conjugate and its use for the treatment of cancer (2022-01-11),

14. 11173131 - Transdermal device including porous microparticles (2021-11-16),

15. 11090298 - Method for treating movement disorders with befiradol (2021-08-17),

Pierre Fabre Médicament is a pharmaceutical company specializing in the research, development, and production of medication. With a focus on dermatology, oncology, and consumer healthcare, Pierre Fabre Medicament provides innovative and effective solutions for various health conditions. Their extensive portfolio includes prescription drugs, over-the-counter products, and cosmetics. Visit their website for more information and to explore their wide range of products and healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

266 Patents

#5 in Boulogne-Billancourt

#88 in France

#3,192 in the World

Boulogne-Billancourt, France

Pierre Fabre Medicament

Forward Citations = 1,168

317 inventors:

Liliane Goetsch (42 out of 44 patents)

Michel Perez (24 out of 24 patents)

Bernard Vacher (22 out of 22 patents)

4. Thierry Imbert (20 out of 22 patents)

5. Jean-François Haeuw (18 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…